pills-384846_960_720-150x150-5307011Governor Cuomo says that controlling the cost of prescription drugs will be part of his agenda in 2020. Four bills currently awaiting his signature or veto give him a chance to get started in 2019.

The medication-related bills were passed by the Legislature earlier this year and recently delivered to his office for final action. Each would intervene in the complex drug market in a different way, but all, if signed, are likely to result in higher overall costs for consumers, employers and taxpayers – adding to what are already the highest premiums in the lower 48 states.

The most sweeping of the three measures, A. 2836/S. 6531, seeks to regulate pharmacy benefit managers (PBMs), the companies that negotiate prices with drug manufacturers on behalf of health plans and employers.

Because the price-setting process is so murky, and because PBMs generate substantial revenues without ever physically handling a product, they are widely distrusted by other players in the health-care system and state lawmakers of both parties.

The regulation bill, cosponsored by Assembly Health Chairman Richard Gottfried and Senate Insurance Chairman Neil Breslin, easily passed in both chambers with bipartisan support – 147-0 in the Assembly and 49-13 in the Senate.

However, the final language came together quickly in the final days of the legislative session, and includes several problematic provisions.

One requires PBMs to act “for the best interests primarily of the covered individual, and the health plan and the provider” – which would be difficult, since the interests of those three groups often conflict. Another clause creates the right to sue PBMs “for any injury or loss … caused by any violation of such duties, obligations or requirements,” which is bound to unleash a lot of costly litigation.

As written, the bill would also subject the companies to overlapping regulation by two state agencies, the departments of Health and Financial Services, which is likely to create redundancy and conflict.

For these and other reasons, the legislation would impede PBMs from fulfilling their core function of negotiating price discounts, which could leave consumers worse off in the end.

A second bill awaiting Cuomo’s final action, A. 2969/S. 2849, would bar insurers from changing their drug formularies (which are often managed by PBMs) in the middle of a plan year. This is meant to protect patients from unexpected coverage changes that could force them to switch medications or pay higher out-of-pocket charges. 

Health plans and employers have objected that this rule would hamstring their ability to manage drug costs – since manufacturers could hike prices early in the year but not lose their formulary slots until months later.

Tellingly, labor unions raised this same objection – and the legislation was promptly amended to exempt collectively bargained plans from its requirements.

The two final bills, A. 2785/S. 3118 and A. 3009/S. 4078, would mandate coverage of drug “synchronization,” in which pharmacies provide partial refills for some medications so that a patient can refill all of his or her prescriptions at once. One bill imposes this requirement on Medicaid, and the other governs private insurance.

The New York Health Plan Association opposes these bills on grounds that they require insurers to pay pharmacists the same fee for partial refills as they do for 30-day refills, which would be likely to increase costs for plans and premium payers.

Earlier this week, Cuomo said his 2020 agenda would include a three-point plan for lowering drug costs: imposing a $100 monthly cap on out-of-pocket insulin costs for insured patients, empowering the Department of Financial Services to investigate price spikes by drug manufacturers, and creating a commission to explore the importation of lower-cost pharmaceuticals from Canada.

The details of those proposals remain to be seen.

Meanwhile, the governor faces a deadline to sign or veto the two drug synchronization bills by Saturday, and the PBM regulation and formulary bills by Dec. 28. Those decisions will be an early signal of how serious he is about truly controlling drug costs.

 

About the Author

Bill Hammond

As the Empire Center’s senior fellow for health policy, Bill Hammond tracks fast-moving developments in New York’s massive health care industry, with a focus on how decisions made in Albany and Washington affect the well-being of patients, providers, taxpayers and the state’s economy.

Read more by Bill Hammond

You may also like

New York Has Widened Its Lead in Per-Capita Spending on Medicaid

New York's per-capita Medicaid spending soared to more than double the nationwide rate in 2018, widening its gap with the other 49 states. Read More

New York’s Medicaid Enrollment Surges to an All-Time High

New York's Medicaid program is growing at its fastest rate in six years, with a quarter-million additional enrollees landing in the safety-net health plan during the first three months of the coronavirus pandemic.  Read More

New York’s Health Premiums Remain Among the Highest in the U.S.

The average cost of New Yorkers' health benefits increased by less than the national average in 2019 but remained among the highest in the U.S., according to recently published federal data. Read More

New York’s Medicaid Roller Coaster Takes an Unusual Turn

The state's Medicaid spending was significantly lower than projected in the first quarter, but that's not necessarily a positive sign for state finances. Read More

Filling in the Blanks of New York’s Coronavirus Pandemic

Because New York was hit with the coronavirus early, before testing was widely available, its official count of infections – at just over 400,000 – vastly understates the scale of its outbreak. Read More

Cuomo Administration Ducks Important Questions on Nursing Homes

A new report from the state Health Department tries to deflect blame for thousands of coronavirus deaths in the state's nursing homes—but undermines its own case by withholding data and engaging in tendentious analysis. Read More

Nursing Home Vacancy Rate Soars, Hinting at a Higher Coronavirus Toll

The vacancy rate in New York's nursing homes has more than doubled since the start of the coronavirus pandemic, suggesting that the death toll among residents may be thousands higher than officially reported. Read More

Unsure of COVID Impact, NY Insurers Roll Dice on Rate Hikes

The health insurance industry's rate applications for 2021, , reveal deep uncertainty about the long-term impact of the coronavirus pandemic on medical costs. Some companies anticip Read More

Subscribe

Sign up to receive updates about Empire Center research, news and events in your email.

CONTACT INFORMATION

Empire Center for Public Policy
30 South Pearl St.
Suite 1210
Albany, NY 12207

Phone: 518-434-3100
Fax: 518-434-3130
E-Mail: info@empirecenter.org

About

The Empire Center is an independent, non-partisan, non-profit think tank located in Albany, New York. Our mission is to make New York a better place to live and work by promoting public policy reforms grounded in free-market principles, personal responsibility, and the ideals of effective and accountable government.